Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Changes in Blood Circulating Cell Populations May Reflect the Anti-Angiogenic and Chemosensitizing Effects of Bortezomib and Thalidomide Treatment in Patients with Multiple Myelomatreatment in Patients with Multiple Myeloma.

Isabelle Vande Broek, MD, PhD, Xavier Leleu, Dan Duda, MD, PhD, Benjamin Van Camp, MD, PhD, Karin Vanderkerken, Ivan van Riet, PhD

Blood (2009) 114 (22): 2807.

https://doi.org/10.1182/blood.V114.22.2807.2807

Published: 2009

Journal Articles

Inhibition of p38α MAPK Reduces Tumor Burden, Prevents the Development of Myeloma Bone Disease, and Increases Survival in the 5T2 and 5T33 Murine Models of Myeloma.

Karin Vanderkerken, PhD, Satya Medicherla, PhD, Les Coulton, PhD, Benjamin Van Camp, MD, PhD, Andy Protter, PhD, Linda Higgins, PhD, Eline Menu, PhD, Peter Croucher, PhD

Blood (2006) 108 (11): 3436.

https://doi.org/10.1182/blood.V108.11.3436.3436

Published: 2006

Journal Articles

Role of the Hypoxic Bone Marrow Microenvironment in Multiple Myeloma Tumor Progression.

Kewal Asosingh, PhD, Hendrik De Raeve, MD, Mark de Ridder, MD, Guy A. Storme, MD, PhD, Angelo Willems, Ivan Van Riet, PhD, Benjamin Van Camp, MD, PhD, Karin Vanderkerken, PhD

Blood (2004) 104 (11): 2348.

https://doi.org/10.1182/blood.V104.11.2348.2348

Published: 2004

Journal Articles

Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity

Kewal Asosingh, Hendrik De Raeve, Eline Menu, Ivan Van Riet, Eric Van Marck, Benjamin Van Camp, Karin Vanderkerken

Blood (2004) 103 (8): 3131–3137.

https://doi.org/10.1182/blood-2003-08-2946

Published: 2004

Journal Articles

Multiple myeloma tumor progression in the 5T2MM murine model is a multistage and dynamic process of differentiation, proliferation, invasion, and apoptosis

Kewal Asosingh, Hendrik De Raeve, Ivan Van Riet, Benjamin Van Camp, Karin Vanderkerken

Blood (2003) 101 (8): 3136–3141.

https://doi.org/10.1182/blood-2002-10-3000

Published: 2003

NARROW

Changes in Blood Circulating Cell Populations May Reflect the Anti-Angiogenic and Chemosensitizing Effects of Bortezomib and Thalidomide Treatment in Patients with Multiple Myelomatreatment in Patients with Multiple Myeloma.

Inhibition of p38α MAPK Reduces Tumor Burden, Prevents the Development of Myeloma Bone Disease, and Increases Survival in the 5T2 and 5T33 Murine Models of Myeloma.

Role of the Hypoxic Bone Marrow Microenvironment in Multiple Myeloma Tumor Progression.

Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity

Multiple myeloma tumor progression in the 5T2MM murine model is a multistage and dynamic process of differentiation, proliferation, invasion, and apoptosis

Email alerts

ASH Publications

American Society of Hematology

Changes in Blood Circulating Cell Populations May Reflect the Anti-Angiogenic and Chemosensitizing Effects of Bortezomib and Thalidomide Treatment in Patients with Multiple Myelomatreatment in Patients with Multiple Myeloma.

Inhibition of p38α MAPK Reduces Tumor Burden, Prevents the Development of Myeloma Bone Disease, and Increases Survival in the 5T2 and 5T33 Murine Models of Myeloma.

Role of the Hypoxic Bone Marrow Microenvironment in Multiple Myeloma Tumor Progression.

Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity

Multiple myeloma tumor progression in the 5T2MM murine model is a multistage and dynamic process of differentiation, proliferation, invasion, and apoptosis

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only